5533861 (SER.L) (SER) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock SER Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA PathwayAugust 25, 2025 | globenewswire.comSerina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business HighlightsAugust 11, 2025 | globenewswire.comSerina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)July 29, 2025 | globenewswire.comSerina Therapeutics to Present at the BTIG Virtual Biotechnology ConferenceJuly 28, 2025 | globenewswire.comSerina Therapeutics Makes Grant to New Employee Under Inducement PlanJuly 10, 2025 | globenewswire.comSerina Therapeutics Announces Date for 2025 Annual Stockholders MeetingJuly 1, 2025 | globenewswire.comSerina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025June 23, 2025 | globenewswire.comUPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42June 17, 2025 | globenewswire.comSerina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42June 17, 2025 | globenewswire.comRegistration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"June 9, 2025 | globenewswire.comSerina Therapeutics Appoints Stephen Brannan, M.D. to Board of DirectorsMay 22, 2025 | globenewswire.comSerina Therapeutics Makes Grants to New Employees Under Inducement PlanMay 14, 2025 | globenewswire.comSerina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 8, 2025 | globenewswire.comSerina Therapeutics to Present at JonesResearch Virtual CNS DayApril 29, 2025 | globenewswire.comSerina Therapeutics to Present at the 4th LNP Formulation & Process Development SummitApril 15, 2025 | globenewswire.comSerina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's DiseaseApril 8, 2025 | globenewswire.comSerina Therapeutics to Present at the Jones Healthcare and Technology Innovation ConferenceApril 7, 2025 | globenewswire.comSerina Therapeutics Reports Full Year 2024 Financial Results and Recent Business HighlightsMarch 24, 2025 | globenewswire.comSerina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 MeetingMarch 24, 2025 | globenewswire.comSerina Therapeutics Appoints Dr. Jay Venkatesan to its Board of DirectorsFebruary 12, 2025 | globenewswire.comSerina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease PatientsFebruary 3, 2025 | globenewswire.comSerina Therapeutics Announces Sale of UniverXome SubsidiaryJanuary 15, 2025 | globenewswire.comSerina Therapeutics Welcomes Karen J. Wilson to its Board of DirectorsJanuary 14, 2025 | globenewswire.comSerina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024December 16, 2024 | globenewswire.comSerina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity SummitDecember 11, 2024 | globenewswire.comSerina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease PatientsDecember 2, 2024 | globenewswire.comSerina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business HighlightsNovember 12, 2024 | globenewswire.comSerina Therapeutics Makes Grants to New Employees Under Inducement PlanNovember 11, 2024 | globenewswire.comSerina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comSerina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business HighlightsAugust 9, 2024 | globenewswire.comSerina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics SummitJuly 29, 2024 | globenewswire.comSerina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and FormulationJuly 18, 2024 | globenewswire.comSerina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business HighlightsMay 14, 2024 | globenewswire.comSerina Therapeutics Appoints Dr. Simba Gill as Executive ChairmanApril 17, 2024 | globenewswire.comSerina Therapeutics Announces Completion of Merger with AgeX TherapeuticsMarch 26, 2024 | globenewswire.com Get 5533861 (SER.L) News Delivered to You Automatically Sign up to receive the latest news and ratings for SER and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SER Media Mentions By Week SER Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SER News Sentiment▼0.001.61▲Average Manufacturing News Sentiment SER News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SER Articles This Week▼00▲SER Articles Average Week Get the Latest News and Ratings for SER and Related Stocks Enter your email address to receive the latest news and analysts' ratings for 5533861 (SER.L) and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AstraZeneca News Today GSK News Today Ithaca Energy News Today HUTCHMED News Today Indivior News Today Grainger News Today Bloomsbury Publishing News Today Origin Enterprises News Today India Capital Growth News Today Aura Energy News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:SER) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 5533861 (SER.L) Please log in to your account or sign up in order to add this asset to your watchlist. Share 5533861 (SER.L) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
